| Name | Title | Contact Details |
|---|---|---|
Amanda Treleaven |
Chief Compliance Officer | Profile |
John LaBarre |
Senior Director, IP Strategy and Commercial Litigation | Profile |
Mina Kim |
Chief Legal Officer and Head of Corporate Development | Profile |
Duane Valz |
General Counsel | Profile |
Duane Valz |
Vice President and General Counsel | Profile |
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.
JMA is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient`s lymph nodes to be used as bioreactors to regrow functioning ectopic organs.
Vitro Naturals is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synovics Pharmaceuticals, Inc. is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.